Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

EGFR mutation + TP53 mutation

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

EGFR mutation + TP53 mutation	Non Small Cell Lung Cancer	EGFR mutation + TP53 mutation	Non Small Cell Lung Cancer	EGFR inhibitor Resistant: B - Late Trials EGFR inhibitor Resistant : B	EGFR inhibitor Resistant: B - Late Trials EGFR inhibitor Resistant : B
EGFR mutation + TP53 mutation	Non Small Cell Lung Cancer	EGFR mutation + TP53 mutation	Non Small Cell Lung Cancer	osimertinib Resistant: C3 – Early Trials osimertinib Resistant : C3	osimertinib Resistant: C3 – Early Trials osimertinib Resistant : C3
EGFR mutation + TP53 mutation	Non Small Cell Lung Cancer	EGFR mutation + TP53 mutation	Non Small Cell Lung Cancer	Tyrosine kinase inhibitor Sensitive: C3 – Early Trials Tyrosine kinase inhibitor Sensitive : C3	Tyrosine kinase inhibitor Sensitive: C3 – Early Trials Tyrosine kinase inhibitor Sensitive : C3
EGFR mutation + TP53 mutation	Lung Adenocarcinoma	EGFR mutation + TP53 mutation	Lung Adenocarcinoma	Tyrosine kinase inhibitor Resistant: C3 – Early Trials Tyrosine kinase inhibitor Resistant : C3	Tyrosine kinase inhibitor Resistant: C3 – Early Trials Tyrosine kinase inhibitor Resistant : C3
EGFR mutation + TP53 mutation	Pancreatic Cancer	EGFR mutation + TP53 mutation	Pancreatic Cancer	PD1 inhibitor Sensitive: C3 – Early Trials PD1 inhibitor Sensitive : C3	PD1 inhibitor Sensitive: C3 – Early Trials PD1 inhibitor Sensitive : C3
EGFR mutation + TP53 mutation	Non Small Cell Lung Cancer	EGFR mutation + TP53 mutation	Non Small Cell Lung Cancer	aumolertinib Sensitive: C3 – Early Trials aumolertinib Sensitive : C3	aumolertinib Sensitive: C3 – Early Trials aumolertinib Sensitive : C3
EGFR mutation + TP53 mutation	Non Small Cell Lung Cancer	EGFR mutation + TP53 mutation	Non Small Cell Lung Cancer	EGFR inhibitor + Angiogenesis inhibitor Sensitive: C3 – Early Trials EGFR inhibitor + Angiogenesis inhibitor Sensitive : C3	EGFR inhibitor + Angiogenesis inhibitor Sensitive: C3 – Early Trials EGFR inhibitor + Angiogenesis inhibitor Sensitive : C3
EGFR mutation + TP53 mutation	Lung Cancer	EGFR mutation + TP53 mutation	Lung Cancer	osimertinib Resistant: C3 – Early Trials osimertinib Resistant : C3	osimertinib Resistant: C3 – Early Trials osimertinib Resistant : C3
EGFR mutation + TP53 mutation	Non Small Cell Lung Cancer	EGFR mutation + TP53 mutation	Non Small Cell Lung Cancer	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3
EGFR mutation + TP53 mutation	Lung Adenocarcinoma	EGFR mutation + TP53 mutation	Lung Adenocarcinoma	EGFR inhibitor Resistant: C3 – Early Trials EGFR inhibitor Resistant : C3	EGFR inhibitor Resistant: C3 – Early Trials EGFR inhibitor Resistant : C3
EGFR mutation + TP53 mutation	Non Small Cell Lung Cancer	EGFR mutation + TP53 mutation	Non Small Cell Lung Cancer	bevacizumab + aumolertinib Sensitive: C3 – Early Trials bevacizumab + aumolertinib Sensitive : C3	bevacizumab + aumolertinib Sensitive: C3 – Early Trials bevacizumab + aumolertinib Sensitive : C3